ATE503474T1 - Endocannabinoid-ähnliche verbindungen und deren verwendung zur behandlung von dermatitis - Google Patents

Endocannabinoid-ähnliche verbindungen und deren verwendung zur behandlung von dermatitis

Info

Publication number
ATE503474T1
ATE503474T1 AT07118561T AT07118561T ATE503474T1 AT E503474 T1 ATE503474 T1 AT E503474T1 AT 07118561 T AT07118561 T AT 07118561T AT 07118561 T AT07118561 T AT 07118561T AT E503474 T1 ATE503474 T1 AT E503474T1
Authority
AT
Austria
Prior art keywords
compounds
pharmacological activity
central
cannabinoid
endocannabinoid
Prior art date
Application number
AT07118561T
Other languages
English (en)
Inventor
Alberta Leon
Carbonare Maurizio Dalle
Fiorenzo Berto
Maria Fusco
Giudice Elda Del
Salvatore Terrazzino
Fabrizio Facchinetti
Antonello Diarrigo
Michele Fabris
Original Assignee
Res & Innovation S P A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Res & Innovation S P A filed Critical Res & Innovation S P A
Application granted granted Critical
Publication of ATE503474T1 publication Critical patent/ATE503474T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT07118561T 2003-02-07 2004-02-06 Endocannabinoid-ähnliche verbindungen und deren verwendung zur behandlung von dermatitis ATE503474T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT000210A ITMI20030210A1 (it) 2003-02-07 2003-02-07 Composti endocannabinoido-simili e loro impiego

Publications (1)

Publication Number Publication Date
ATE503474T1 true ATE503474T1 (de) 2011-04-15

Family

ID=32843894

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07118561T ATE503474T1 (de) 2003-02-07 2004-02-06 Endocannabinoid-ähnliche verbindungen und deren verwendung zur behandlung von dermatitis

Country Status (7)

Country Link
EP (2) EP1592418B1 (de)
AT (1) ATE503474T1 (de)
DE (1) DE602004032066D1 (de)
ES (1) ES2364087T3 (de)
IT (1) ITMI20030210A1 (de)
PT (1) PT1900365E (de)
WO (1) WO2004069240A2 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12012502423B1 (en) * 2010-07-02 2018-01-12 Helix Biomedix Inc N-acyl amino acid derivatives for treating skin conditions such as cellulite
US10647903B2 (en) 2017-08-15 2020-05-12 Saudi Arabian Oil Company Oil-based drilling fluid compositions which include layered double hydroxides as rheology modifiers and amino amides as emulsifiers
CN111032818A (zh) 2017-08-15 2020-04-17 沙特阿拉伯石油公司 油基钻井液的热稳定表面活性剂
US10988659B2 (en) 2017-08-15 2021-04-27 Saudi Arabian Oil Company Layered double hydroxides for oil-based drilling fluids
US10745606B2 (en) 2017-08-15 2020-08-18 Saudi Arabian Oil Company Oil-based drilling fluid compositions which include layered double hydroxides as rheology modifiers
US10640696B2 (en) 2017-08-15 2020-05-05 Saudi Arabian Oil Company Oil-based drilling fluids for high pressure and high temperature drilling operations
US10876039B2 (en) 2017-08-15 2020-12-29 Saudi Arabian Oil Company Thermally stable surfactants for oil based drilling fluids
US10793762B2 (en) 2017-08-15 2020-10-06 Saudi Arabian Oil Company Layered double hydroxides for oil-based drilling fluids
US10676658B2 (en) 2017-08-15 2020-06-09 Saudi Arabian Oil Company Oil-based drilling fluids for high pressure and high temperature drilling operations
KR102701244B1 (ko) 2017-10-23 2024-09-02 에피트래커, 인코포레이티드 지방산 유사체 및 대사 증후군 관련 병태 치료에서의 그의 용도
AU2019274431B2 (en) 2018-05-23 2025-03-13 Epitracker, Inc. Compositions and methods for diagnosis and treatment of conditions related to the quality of aging and longevity
EP3908374A4 (de) 2019-01-09 2022-12-28 Epitracker, Inc. Zusammensetzungen und verfahren zur diagnose und behandlung von neurodegenerativen erkrankungen
JP7404382B2 (ja) 2019-03-04 2023-12-25 エピトラッカー インコーポレイテッド 脂肪酸アナログ、ならびに認知機能障害、行動症状および慢性疼痛の処置におけるそれらの使用
IL297869A (en) * 2020-05-04 2023-01-01 Tufts College Synthetic lipid-like agents for administration in the brain
EP4426130A1 (de) 2021-11-03 2024-09-11 Epitracker, Inc. Pentadecanoylcarnitin zur behandlung von alterungs- und langlebigkeitsbedingten leiden
EP4647065A1 (de) 2024-05-09 2025-11-12 Laboratorio della Farmacia S.p.A. Vehicle fuer acylamides basiert auf alkyl ether derivativen vonpolyethylene glycol

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4049824A (en) * 1976-05-03 1977-09-20 Harry Weldon Diehl Cetyl myristoleate
US5231087A (en) * 1988-03-16 1993-07-27 Cellegy Pharmaceuticals, Inc. Treatment of skin diseases and tumors with esters and amides of monocarboxylic acids
US5409693A (en) * 1989-10-12 1995-04-25 Perricone; Nicholas V. Method for treating and preventing sunburn and sunburn damage to the skin
US5605929A (en) * 1992-05-27 1997-02-25 Arch Development Corp. Methods and compositions for inhibiting 5α-reductase activity
IL103932A (en) * 1992-11-30 1997-02-18 Yissum Res & Dev Fatty acid and pharmaceutical compositions containing them
DE4434781A1 (de) * 1994-09-29 1996-04-04 Beiersdorf Ag Verwendung von Fettsäureestern zur Bekämpfung von Superinfektionen
AU723064B2 (en) * 1995-08-25 2000-08-17 Dow Agrosciences Llc Compositions having synergistic fungitoxic effects
US6417227B1 (en) * 1999-04-28 2002-07-09 Cg And Associates Methods of delivery of cetyl myristoleate
AU1953701A (en) * 1999-12-09 2001-06-18 Bruce Levin Methods and compositions for treatment of inflammatory disease
FR2803749B1 (fr) * 2000-01-18 2006-09-22 Pharmascience Lab Utilisation d'au moins un ester gras pour la preparation d'une composition destinee a inhiber l'activite de la 5 alpha-reductase, en pharmacie notamment en dermatologie, en cosmetique et en tant qu'additif alimentaire
AU2001288325A1 (en) * 2000-09-22 2002-04-02 Eli Lilly And Company Pharmaceutical compounds useful as modulators of endocannabinoid-mediated response
IL142537A0 (en) * 2001-04-11 2002-03-10 Yeda Res & Dev Pharmaceutical compositions for the treatment of autoimmune diseases
ITMI20011483A1 (it) * 2001-07-11 2003-01-11 Res & Innovation Soc Coop A R Uso di composti come antagonisti funzionali ai recettori centrali deicannabinoidi
WO2003026640A1 (en) * 2001-09-28 2003-04-03 Meracol Corporation Limited Treating food allergies and/or food intolerances
MXPA04004532A (es) * 2001-11-19 2004-08-11 Medigene Ag Medicamento para el tratamiento de enfermedades tumorales y virales de la piel.
JP4450406B2 (ja) * 2002-01-16 2010-04-14 学校法人日本大学 ベニカミキリフラスを有効成分とする皮膚外用薬

Also Published As

Publication number Publication date
ITMI20030210A1 (it) 2004-08-08
DE602004032066D1 (de) 2011-05-12
EP1592418A2 (de) 2005-11-09
EP1900365A3 (de) 2008-07-23
WO2004069240A3 (en) 2004-11-11
WO2004069240A2 (en) 2004-08-19
EP1900365A2 (de) 2008-03-19
PT1900365E (pt) 2011-07-21
EP1900365B9 (de) 2012-01-18
EP1900365B1 (de) 2011-03-30
ES2364087T3 (es) 2011-08-24
EP1592418B1 (de) 2017-09-06

Similar Documents

Publication Publication Date Title
ATE503474T1 (de) Endocannabinoid-ähnliche verbindungen und deren verwendung zur behandlung von dermatitis
Yamamoto et al. Psychiatric symptoms of noradrenergic dysfunction: a pathophysiological view
Hong et al. Beta (∼ 16 Hz) frequency neural oscillations mediate auditory sensory gating in humans
Hudson et al. Reversal of evoked gamma oscillation deficits is predictive of antipsychotic activity with a unique profile for clozapine
WO2005044190A3 (en) Compositions and methods for treatment of nervous system disorders
Lafrance et al. Diurnal variations in the waking EEG: comparisons with sleep latencies and subjective alertness
DE602004026767D1 (de) Immunsorbens-bluttests zur beurteilung von paroxysmalen zerebralentladungen
DE602004010407D1 (de) Fluorsubstituierter omega-carboxyaryldiphenylharnstoff zur behandlung und prävention von krankheiten und leiden
DE60329123D1 (de) Benzoädüazepinderivate für die behandlung von neurologischen krankheiten
ATE396202T1 (de) Lang wirkendes glucagon-ähnliches peptid-2 für die behandlung von gastrointestinalen krankheiten und störungen
ATE527016T1 (de) System zur überwachung oder behandlung von erkrankungen des nervensystems
Nitzan et al. Initial evaluation of pain intensity among depressed patients as a possible mediator between depression and pain complaints
DE60231107D1 (de) Tetrahydro-pyrazinoä1,2-aüindole für die behandlung von krankheiten des zentralnervensystems
Yalýn et al. A comparison of the circadian rhythms and the levels of melatonin in patients with diurnal and nocturnal complex partial seizures
DE602004023762D1 (de) Für die behandlung von alzheimer-krankheit und ähnlichen leiden geeignete 1-alkyl-3-thiosubstituierte indol-2-alkinsäuren
ATE425752T1 (de) Verwendung von pipamperon und einem sndri, snri oder ssri zur behandlung von stimmungs- oder angststírungen
ATE489361T1 (de) Derivate von alpha-phenylthiocarbon- und alpha- phenyloxycarbonsäuren, die für die behandlung von auf die aktivierung von ppar alpha ansprechende krankheiten geeignet sind
ATE271861T1 (de) Verwendung von nmda-antagonisten und/oder natriumkanalantagonisten zur behandlung von entzündlichen erkrankungen
DE60122673D1 (de) Methoden zur diagnose und behandlung von herzkrankheiten
EA200801302A1 (ru) Композиции и способы лечения нарушений цнс
ATE494903T1 (de) Verwendung von slurp-1 zur behandlung von krankheiten, die durch störungen der acetylcholinerezeptoren ausgelöst werden
Chieffo et al. Preoperative neuropsychological and behavioral evaluation of children with thalamic tumors
Hickie et al. The utility of clinical staging in youth mental health settings: Neurobiological and longitudinal data from Sydney-based studies of transdiagnostic cohorts.
Dejakaisaya et al. Effect of ceftriaxone on the glutamate-glutamine cycle and seizure susceptibility of Tg2576 mouse model of Alzheimer's disease
Hummel et al. Olfactory processing in children and young adults

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1900365

Country of ref document: EP